NeuroPace Inc
NPCE Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$12.99
KIRA · Stoqly’s AI analyst, in plain words
- NeuroPace Inc had $100.0M of revenue in fiscal 2025, up 25.1% on the year before. Over five years, revenue changed +19.4% a year on average.
- Its operating margin was −16.3%, up 10.8 pts: of every 100 in sales, about −16 is left after running the business.
- NeuroPace Inc lost $21.5M in fiscal 2025.
- Free cash flow was −$11.3M in fiscal 2025, −11.3% of revenue.
- NeuroPace Inc returned $49.5M to shareholders in fiscal 2025. The diluted share count rose 12.3%.
- NeuroPace Inc has $2.2M more cash than debt.
Market cap
$443M
P/E
—
Revenue
$100.0M
Net income
−$21.5M
Free cash flow
−$11.3M
Operating margin
−16.3%
NeuroPace Inc in 30 seconds · fiscal 2025
Are sales growing?
+25.1%
Yes. Sales grew 25.1% last year.
Does it make a profit?
−21.5%
No. It lost money last year.
Does profit turn into cash?
−11.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NeuroPace Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- NeuroPace Inc
- CIK
- 0001528287
NeuroPace Inc · NPCE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Revenue growth | 9.8% | 0.7% | 43.7% | 22.1% | 25.1% |
| Gross margin | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Operating margin | −52.5% | −89.6% | −41.5% | −27.1% | −16.3% |
| Net income | −$36.1M | −$47.1M | −$33.0M | −$27.1M | −$21.5M |
| Net margin | −79.9% | −103.4% | −50.4% | −34.0% | −21.5% |
| Diluted EPS | −$2.17 | −$1.91 | −$1.27 | −$0.93 | −$0.66 |
| Cash | |||||
| Cash from operations | −$24.6M | −$36.9M | −$19.7M | −$17.9M | −$11.0M |
| Capital expenditure | $0.4M | $0.6M | $0.2M | $0.3M | $0.3M |
| Free cash flow | −$25.0M | −$37.5M | −$19.9M | −$18.3M | −$11.3M |
| FCF margin | −55.2% | −82.3% | −30.4% | −22.8% | −11.3% |
| Share buybacks | — | — | — | $0.0M | $49.5M |
| Share count change | 8,037.6% | 48.1% | 5.1% | 12.7% | 12.3% |
| Debt and strength | |||||
| Cash and short-term investments | $116M | $77.4M | $66.5M | $52.8M | $61.1M |
| Debt incl. finance leases | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M |
| Shareholders' equity | $73.5M | $34.8M | $20.7M | $8.0M | $19.0M |
| Current ratio | 14.3x | 8.9x | 5.7x | 5.4x | 5.3x |
| Interest coverage | −3.2x | −5.4x | −3.2x | −2.5x | −2.2x |
| Returns and quality | |||||
| Return on capital | −241.5% | −313.5% | −192.5% | −115.8% | −76.6% |
| Return on equity | — | −87.0% | −118.9% | −189.4% | −158.7% |
| Return on tangible equity | −49.1% | −135.4% | −159.6% | −338.7% | −112.8% |
| Piotroski F-score | 5 | 2 | 4 | 4 | 5 |
| Altman Z'' | −4.2 | −10.4 | −12.0 | −15.1 | −13.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
1 insider
Of sales under plans
100%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NeuroPace Inc · NPCE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.99 a share, the company is worth $443M.
Source: SEC EDGAR XBRL filings (CIK 0001528287). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.